Skip to content
    IPGP
    Earnings call· Jun 2026(Q2 FY26)

    IPG PHOTONICS Q2 FY26 earnings call IPGP

    Aug 4, 2026 Source

    Executive summary

    IPG Photonics Q2 FY26 — Strong Revenue Growth and Strategic Acquisitions Drive Performance

    IPG Photonics delivered a strong second quarter, exceeding revenue and adjusted profitability expectations, driven by robust demand in industrial applications and sequential improvement in advanced solutions. The company is actively executing on strategic growth initiatives, including the acquisition of Lumibird Medical to expand into higher-margin medical markets and advancing its directed energy defense system. Management remains confident in long-term demand trends and continued margin expansion through cost optimization and operational efficiency.

    Highlights

    5

    • Total revenue of $279 million, up 11% year-over-year, marking the third consecutive quarter of double-digit growth.

    • Adjusted gross margin of 40.7% and adjusted EPS of $0.58, both above the top end of guidance.

    • Book-to-bill remained above 1 for the third consecutive quarter, indicating sustained demand.

    • Industrial Solutions revenue increased 16% year-over-year, led by battery manufacturing, cleaning, and additive manufacturing.

    • Advanced Solutions revenue improved 10% quarter-over-quarter, driven by strong growth in semiconductor applications.

    Concerns

    4

    • North American revenue decreased 2% year-over-year due to lower sales in cutting, defense, and medical applications.

    • Advanced Solutions revenue decreased 9% compared to last year, despite sequential improvement, due to lower micromachining and defense revenue.

    • Ongoing impact from tariffs of about 150 basis points expected to affect Q3 gross margin.

    • Manufacturing cost absorption remains below target levels, despite positive benefits from lower inventory provisions and product costs.

    Guidance & targets

    8
    CategoryTargetConfidence
    Q3 FY26 Revenue
    $265 million to $295 million
    high materiality
    High
    Q3 FY26 Adjusted Gross Margin
    37.5% to 40.5%
    high materiality
    High
    Q3 FY26 Adjusted Operating Expenses
    $92 million to $95 million
    medium materiality
    High
    Q3 FY26 Adjusted EPS
    $0.30 to $0.60
    high materiality
    High
    Q3 FY26 Adjusted EBITDA
    $35 million to $51 million
    medium materiality
    High
    FY26 Capital Expenditures
    $90 million to $100 million
    medium materiality
    High
    Medical Business Growth
    more than double
    medium materiality
    High
    Operating Expenses
    modestly increase
    low materiality
    Medium

    Segment performance

    5
    SegmentRevenueYoYQoQMargin
    Industrial Solutions
    Growth driven by welding, marking, cleaning, and additive manufacturing. Sequential growth primarily due to strength in welding and cleaning.
    		—16%4%—
    Advanced Solutions
    Year-over-year decrease due to lower revenue in micromachining and defense, offset by semiconductor growth. Sequential improvement driven by semiconductor and micromachining applications.
    		—-9%10%—
    North America
    Year-over-year decrease due to lower revenue in cutting, defense, and medical applications. Sequential increase due to increased marketing and defense sales.
    		—-2%1%—
    Europe
    Growth driven by increased sales in cleaning and additive manufacturing, partially offset by a decrease in cutting.
    		—5%1%—
    Asia
    Growth driven by strong welding applications, benefiting from higher demand in battery manufacturing.
    		—19%8%—

    Operational metrics

    17
    Total Revenue
    $279 millionup 11% YoY
    Q2 FY26

    Above the midpoint of guidance, marking the third consecutive quarter of double-digit year-over-year growth.

    Adjusted Gross Margin
    40.7%
    Q2 FY26

    Above the top end of guidance range.

    Adjusted Operating Expenses
    $91 milliondeclined sequentially
    Q2 FY26

    Came in slightly below guidance range due to German R&D tax credit.

    Adjusted EPS
    $0.58
    Q2 FY26

    Above the top end of guidance range.

    Adjusted EBITDA
    $49 million
    Q2 FY26

    Above the top end of guidance range.

    Cash and investments balance
    $871 million
    Q2 FY26

    Includes cash, cash equivalents, and short-term investments.

    Long-term investments
    $33 million
    Q2 FY26

    Balance at quarter end.

    Debt
    no debt
    Q2 FY26

    No outstanding debt at quarter end.

    Capital expenditures
    $21 million
    Q2 FY26

    Spend during the second quarter.

    Year-to-date Capital expenditures
    $37 million
    YTD Q2 FY26

    Cumulative CapEx for the first half of the fiscal year.

    Underlying CapEx as % of revenue
    5%
    Q2 FY26

    Expected to maintain this level going forward.

    Diluted common shares outstanding
    43 million
    Q3 FY26 estimate

    Used for Q3 FY26 adjusted EPS guidance.

    Tariff refunds benefit to gross margin
    $4.7 million
    Q2 FY26

    Positive impact on gross margin in the quarter.

    German R&D tax credit benefit to operating expenses
    $1.8 million
    Q2 FY26

    Benefited adjusted operating expenses in the quarter.

    FX benefit to revenue
    2%YoY
    Q2 FY26

    Foreign currency benefited revenue compared to the prior year period.

    Emerging Growth Products as % of total revenue
    58%up from 53% in prior quarter
    Q2 FY26

    Driven by strong growth in lasers and solutions for battery manufacturing processes.

    Medical business as % of total revenue
    7% to 8%
    Q2 FY26

    Current approximate size of the medical business.

    Industry KPIs

    6
    MetricValueDetails
    M a contributionaccretive to gross margin, EBITDA, and adjusted EPS in the first year
    Orders book to billabove 1
    Segment revenue growthIndustrial Solutions +16% YoY; Advanced Solutions -9% YoY%
    Design wins product cycle rampsrecent wins with 2 major global automotive manufacturers; new business with large semiconductor equipment manufacturers
    End market revenue mix organic growthNorth America -2% YoY; Europe +5% YoY; Asia +19% YoY; China 34% of revenue%
    Operating margin incremental leverage40.7%%

    Orderbook & backlog

    2
    Book-to-bill ratioabove 1Q2 FY26

    remained above 1

    Third consecutive quarter above 1, indicating sustained demand.

    Medical bookings and backlogstrongQ2 FY26

    Expected to drive increased shipments in the second half of the year.

    Product announcements

    2
    ProductTypeDetails
    Latest generation of lasers with proprietary beam shaping capabilitieslaunch
    Medical product approvals and introductionsroadmap

    Deals & partnerships

    1
    Lumibird MedicalAcquisition of a global leader in diagnostic and treatment systems for ophthalmology.

    Accelerates IPG's strategic evolution by expanding Advanced Solutions into attractive, higher-margin medical markets, strengthening business mix quality, and creating a scaled medical laser platform.

    Capital programs

    1
    Major fiber manufacturing facility in Germanyunderway

    Investments in this facility are included in the FY26 CapEx outlook of $90 million to $100 million.

    Risks & headwinds

    3
    Geopolitical environment and higher oil pricesongoing

    impact in Europe

    Tariff impact on gross marginQ3 FY26

    150 basis points

    Mitigation: Factored into Q3 gross margin guidance.

    Manufacturing cost absorptionmedium term

    below target

    Mitigation: Several initiatives are underway to drive manufacturing efficiency and improve absorption.

    What to watch in Q3 FY26

    5

    Medical business growth

    next quarter and beyond
    Current7% to 8% of total revenue
    Targetprogress towards doubling in 2-3 years

    Why it matters

    Medical is a higher-margin market, and its growth trajectory, especially with the Lumibird acquisition, is key to business mix quality and profitability.

    We have very strong demand and backlog in medical, and we're confident that we're going to have another good year continue to -- we're continuing to advance in the innovation road map there with new product approvals and introductions that are planned in 2026 and 2027. And I talked about those, of course, Jim, we talked about the fact that we launched a key new product at the end of last year, we picked up a new key customer the fact that we have both systems as well as the disposable fibers. So those are all moving strongly and as I've talked about in the past, we expect to more than double the business over the next 2 to 3 years.

    Q&A highlights

    6

    Given three consecutive quarters of book-to-bill above 1, how does the Q3 revenue guidance, which is roughly flat at the midpoint, relate to the building of shippable backlog and future quarters?

    Management reiterated strong double-digit year-over-year growth for three quarters and a book-to-bill above 1, indicating encouraging signs across the business. They highlighted positive progress in Industrial Solutions with differentiated offerings and stable, expansive global PMIs, alongside positive momentum in Advanced Solutions.

    “So just to step back for a second, of course, as you mentioned, we're seeing double-digit growth year-over-year, and this is the third quarter in a row for that. Book-to-bill, again, was strong, it was above 1 for the third quarter in a row. And we're really seeing encouraging signs across the business.”

    asked by Ruben Roy · answered by Mark Gitin

    2 min read7 chapters

    Detailed Narrative

    01

    Strategic Growth Initiatives and Operational Transformation

    IPG Photonics is pursuing two strategic growth initiatives: strengthening leadership in industrial solutions and expanding into attractive advanced solutions markets. The company is streamlining operations and accelerating product development through its 'One IPG operating model' to maximize growth and profit opportunities. This transformation aims to improve performance and consistency across the business, positioning IPG for above-market growth and margin expansion.

    02

    Industrial Solutions Strength and Battery Manufacturing

    Revenue growth in Industrial Solutions was primarily driven by welding applications, particularly in battery manufacturing for electric vehicles and stationary storage. The company's unique adjustable mode beam lasers, advanced beam delivery, and real-time process monitoring enable unmatched welding speed and quality, leading to recent wins with major global automotive manufacturers. Demand for high-capacity batteries, supported by data centers and renewables, continues to drive strong bookings and pull in this area.

    03

    Advanced Solutions Progress and Semiconductor Growth

    Advanced Solutions saw sequential improvement, led by strong growth in semiconductor applications. IPG is winning new business with large semiconductor equipment manufacturers for lithography, metrology, and inspection solutions, leveraging differentiated value and performance advantages. This growth is linked to accelerated AI-related demand for GPUs and high-bandwidth memory chips, increasing IPG's exposure to this high-growth market.

    04

    Lumibird Medical Acquisition

    IPG Photonics entered into a binding offer to acquire Lumibird Medical, a global leader in ophthalmology diagnostic and treatment systems. This acquisition is expected to accelerate IPG's strategic evolution by expanding Advanced Solutions into higher-margin medical markets, improve profitability, and create a scaled medical laser platform. The deal, expected to close in Q4 2026, will increase IPG's addressable medical market by approximately $1 billion.

    05

    CROSSBOW Defense System Development

    The company began shipping Lockheed Martin's order for the CROSSBOW directed energy defense system and expects more units to ship in Q3. Recent successful tests at White Sands missile range demonstrated CROSSBOW's capabilities in harsh environments and cooperative engagement tactics. Management remains optimistic about the emerging directed energy market, believing CROSSBOW's compelling cost-to-exchange ratio provides an effective solution against drone threats for both military and civilian infrastructure.

    06

    Gross Margin Improvement Initiatives

    IPG is focused on driving gross margin improvements through several initiatives, including reducing product costs by moving to higher-power optical components like diodes. The company is also optimizing pricing in areas of strong differentiation and driving manufacturing efficiency to improve absorption and utilization. These efforts, coupled with increasing business scale, are expected to lead to continued gross margin expansion into 2027.

    07

    China Market Dynamics and Additive Manufacturing

    China remains a significant industrial market for IPG, contributing 34% of revenue. The company is gaining share due to differentiated solutions, particularly in battery welding and additive manufacturing, winning against both local and Western competitors. In additive manufacturing, new lasers with specialized mode qualities have improved throughput by 1.5 to 2 times, reducing cost per part and expanding market applications from aerospace to medical and consumer devices. Pricing power is maintained in these differentiated areas.

    AI-generated summary of the company’s earnings call. Not investment advice.